PacBio and ILLUMINAA few months ago PACB and ILMN were mentioned in an article by Travis and several comment threads. Part of the discussion was whether the tease in question, I believe by Jeff Brown, was referring to PACB or ILMN. I ended up purchasing both simply because I find the long term potential within the field […]
Articles
We won’t be posting a Friday File next week due to the Thanksgiving holiday, and publishing will be light in general for the next few days for the same reason (though we will, of course, feature our annual Turkey of the Year) … so perhaps you can take some solace in the fact that this […]
[ed. note: We’re getting questions about this ad, so perhaps it’s circulating again — to help answer those questions, we’re re-posting this article that we originally published last November when we saw the first version of this ad. The Irregulars Quick Take has been updated above, but what follows has not been updated, changed or […]
As a reformed academic, I have it hard-wired in my brain that work should cease for the week between Christmas and New Year’s Day — Stock Gumshoe will be running on autopilot starting this afternoon, and we’re not likely to have much in the way of new articles posted until next year (unless you want […]
Frank Curzio has been around the block a few times, helming mostly small-cap newsletters for three different big publishers over the last decade or so — his current “entry level” newsletter for Uncommon Wisdom/Weiss is called Disruptors and Dominators, and he’s selling it today by touting the possibility of 2,997% gains from the advancing science […]
This article originally ran on January 12… the teaser pitch was still being circulated heavily last week, and the stock released earnings on February 3 that disappointed investors, bringing shares down about 15% (it was teased as a “$7 biotech,” and briefly $8, before then). The original Jan. 14 “special event” catalyst teased by Lichtenfeld, […]
I suppose I should expect this by now — whenever Frank Curzio and the gang put out a teaser for Phase 1 Investor, which is the big-money newsletter from Stansberry & Associates ($5,000/year, though almost always “on sale” at $3,000 when they’re running promos), my inbox gushes like Spindletop. Didn’t matter if it was a […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I understood that PACB was a leading DNA machine producer...bought 200 shares at $35...
PACB is the one I came up with also. In the video I watched, he kept mentioning, the investment now would be like buying...
I don't know where you get that idea, Illumina is a major manufacturer of sequencing machines -- they use contract manuf...
I haven't written about this teaser pitck, but Illumina (ILMN) is one of the largest makers of sequencing machines in th...
It's not ILMN, its PACB. He specifically says its the company "making" the sequencer...not doing the analysis in the lab...
Finally worked out for hopeful PACB shareholders... as long as you didn't buy during late 2015 or 2016. I have no idea ...
Yes. What is this? Pacific Biosciences? Any other guesses?...
$PACB Pacific Biosciences Benny Hill queried on a teaser from Oxford. Small company about to z...
Hey Benny, I think the Oxford teaser is Pacific Biosciences. Can't find your original post but saw the link and Pac B...
http://globalbiodefense.com/2014/07/22/cdc-award-genome-sequencing-meningococcus/ Pacific BioSciences PACB Would appre...
Need some help on these tickers, they look interesting to me or other readers. Please volunteer if you are able to pick...
I got this today and wondered if anyone knew anything? Im reliably told its Pacific BioSciences $PACB. On January 14, 2...